Abstract PR10: Reprogramming Myeloid Cells in TME with Pepinemab, First-in-class Semaphorin 4D MAb, Enhances Combination Immunotherapy
CANCER IMMUNOLOGY RESEARCH(2019)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined